U07.1
Conditions
Interventions
Group 1: Recovered patients after asymptomatic course of SARS-CoV-2 infection.
Group 2: Healthy controls.
Group 3: Recovered patients after severe course of SARS-CoV-2 infection.
Sponsors
Klinik für Neurodegenerative Erkrankungen und GerontopsychiatrieUniversitätsklinikum Bonn
Eligibility
Sex/Gender
All
Age
25 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patient subjects must belong to one of the following: Asymptomatic or severly affected course of COVID-19 (SARS-CoV-2 positive) infection. Both groups must meet the following criteria: - written informed consent of the subject - aged 25 to 75 years - fulfill the criteria for the respective groups of interest; either to the group of remitted COVID-19 infection cases with an asymptomatic couse (i.e., no symptoms other than anosmia and/or ageusia) or to the group of remitted COVID-19 infection cases with a severe course (i.e., requiring hospital stay) - able and willing to participate throughout the study - fluent German language abilities Healthy controls will only be included if they meet all of the following criteria - written informed consent aged 25 to 75 years fluent German language abilities - deny memory concerns - memory performance is above - 1.0 SD od the mean on a cognitive screening of episodiv memory impariment - no substance abuse - no known history of or current diagnosed psychiatric illness
Exclusion criteria
Exclusion criteria: - inability to give informed consent - any condition that clearly interferes with participation in the study - any condition that interferes with the clinical or neuropsychological study procedures - sensory impairment that prevents or significantly interferes with neuropsychological testing - contraindication for MRI - severe or unstable medical condition - current major depressive episode - psychotic disorder, bipolar disorder, substance abuse at present or in the past - known neurodegenerative disorder (Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Huntington's disease, Amyotrophic Lateral Sclerosis) - vascular dementia, history of stroke, or history of malignant disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint of the investigation ist the total episodic memory score taken from the long delayed verbal recall parameters of the Auditive Word List Test (AWLT) from within the Vienna Test System Cognitive Functions Dementia (Kognitive Funktionen Demenz) Version 2 - Revision 2 von Mödling, Jänner 2019 at the 12 month visit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are as follows: - Neurodegeneration assessed by volumetric MRI - Changes in serum biomarkers of neurodegeneration - Pulmonary dysfunction and development of lung fibrosis - Activities of daily living - Health-related quality of life | — |
Countries
Germany
Contacts
Public ContactCatherine N. Widmann
Klinik für Parkinson-, Schlaf- und Bewegungsstörung, Universitätsklinikum Bonn
Outcome results
None listed